Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system

被引:23
|
作者
Zimmerman, Robert S. [1 ]
Hobbs, Todd M. [2 ]
Wells, Brian J. [3 ]
Kong, Sheldon X. [2 ]
Kattan, Michael W. [4 ]
Bouchard, Jon [2 ]
Chagin, Kevin M. [4 ]
Yu, Changhong [4 ]
Sakurada, Brian [2 ]
Milinovich, Alex [4 ]
Weng, Wayne [2 ]
Bauman, Janine M. [4 ]
Pantalone, Kevin M. [1 ]
机构
[1] Cleveland Clin, Endocrinol, Cleveland, OH 44106 USA
[2] Novo Nordisk, Plainsboro, NJ USA
[3] Wake Forest Sch Med, Clin & Translat Sci Inst, Winston Salem, NC USA
[4] Cleveland Clin, Quantitat Hlth Sci, Cleveland, OH 44106 USA
来源
DIABETES OBESITY & METABOLISM | 2017年 / 19卷 / 11期
关键词
glucagon-like peptide-1 receptor agonist; cardiovascular risk; cardiovascular disease; mortality; type-2; diabetes; PROTAMINE HAGEDORN INSULIN; TO-TARGET TRIAL; GLYCEMIC CONTROL; BASAL INSULIN; COMBINATION THERAPY; PLUS METFORMIN; NPH INSULIN; GLARGINE; PREDICTORS; HYPOGLYCEMIA;
D O I
10.1111/dom.12969
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To assess the potential impact of glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure on cardiovascular disease (CVD) and mortality outcomes in patients with type 2 diabetes (T2D), using a large retrospective cohort. Research Design and Methods: Patients who had T2D between 2005 and 2014 (N = 105 862) were identified from the electronic health record system at Cleveland Clinic using a validated electronic phenotype. A time-dependent, Cox, multiple regression analysis was used to assess the association between GLP-1RA exposure and risk of acute myocardial infarction (AMI), stroke/cerebrovascular accident (CVA), and overall mortality, as well as the composite of all three outcomes. The findings were further evaluated by assessing the effect of GLP-1RAs on the same variables in patients with and without prior CVD. The model adjusted for differences in demographic information, hypertension, laboratory/vital signs, history of outcomes, and T2D medications. Results: There were significantly lower rates of AMI (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.65 to 0.99; P =.045), CVA (HR 0.82, 95% CI 0.74 to 0.91, P <.001), overall mortality (HR 0.48, 95% CI 0.41 to 0.57; P <.001), and the composite outcome (HR 0.82, 95% CI 0.74 to 0.91; P <.002) during the consolidated time that patients were exposed to GLP-1RAs compared to corresponding rates during intervals without GLP-1RA exposure. GLP-1RA treatment was associated with a significant decrease in CVA, mortality, and the composite outcome in patients with and without established CVD, not significantly affecting AMI in these subgroups. Conclusions: GLP-1RA exposure was found to be associated with a reduction in the risk of cardiovascular events observed and overall mortality among patients with T2D with and without established CVD, after adjusting for potential confounders.
引用
下载
收藏
页码:1555 / 1561
页数:7
相关论文
共 50 条
  • [1] Initiating a Glucagon-like Peptide-1 Receptor Agonist in the Management of Type 2 Diabetes Mellitus
    Gavin, James R., III
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2012, 112 (01): : S16 - S21
  • [2] Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes
    Yen, Fu-Shun
    Hou, Ming-Chih
    Wei, James Cheng-Chung
    Shih, Ying-Hsiu
    Hsu, Chung Y.
    Hsu, Chih-Cheng
    Hwu, Chii-Min
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (06) : 1255 - 1264.e18
  • [3] MEDICATION USE AND TREATMENT PATTERNS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES MELLITUS
    Johnston, S. S.
    Nguyen, H.
    Felber, E.
    Cappell, K.
    Nelson, J.
    Chu, B. C.
    Kalsekar, I
    VALUE IN HEALTH, 2014, 17 (03) : A261 - A262
  • [4] Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus
    Davis, Portia N.
    Ndefo, Uche Anadu
    Oliver, Ashley
    Payton, Enryka
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (13) : 1097 - 1103
  • [5] Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus
    Harris, Kira B.
    McCarty, Delilah J.
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2015, 6 (01) : 3 - 18
  • [6] Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes
    Bensignor, Megan O.
    Wolf, Jack M.
    Rudser, Kyle D.
    Kelly, Aaron S.
    Arslanian, Silva
    DIABETES OBESITY & METABOLISM, 2022, 24 (07): : 1380 - 1384
  • [7] Improving Glucagon-like Peptide-1 Dynamics in Patients With Type 2 Diabetes Mellitus
    Freeman, Jeffrey S.
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2012, 112 (01): : S2 - S6
  • [8] Adherence to glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study
    Lassen, Mats C. H.
    Johansen, Niklas Dyrby
    Modin, Daniel
    Catarig, Andrei-Mircea
    Vistisen, Bodil Kjeldgaard
    Amadid, Hanan
    Zimmermann, Esther
    Gislason, Gunnar
    Biering-Sorensen, Tor
    DIABETES OBESITY & METABOLISM, 2024,
  • [9] Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetes
    Rizzo, Manfredi
    Rizvi, Ali A.
    Sesti, Giorgio
    DIABETES OBESITY & METABOLISM, 2017, 19 (05): : 613 - 614
  • [10] Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients
    Hopkins, N. D.
    Cuthbertson, D. J.
    Kemp, G. J.
    Pugh, C.
    Green, D. J.
    Cable, N. T.
    Jones, H.
    DIABETES OBESITY & METABOLISM, 2013, 15 (08): : 770 - 773